Advertisement
Advertisement
DBVT
DBV Technologies S.A. - ADR
12.28
USDSponsored
-0.36
-2.81%
Sep 23, 14:00 UTC -4
Open
DBVT Earnings Reports
Positive Surprise Ratio
DBVT beat 11 of 19 last estimates.
58%
Next Report
Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
$828.20K
/-$0.09
Implied change from Q2 26 (Revenue/ EPS)
+18.31%
/-25.00%
Implied change from Q3 25 (Revenue/ EPS)
-70.14%
/-62.50%
DBV Technologies S.A. - ADR earnings per share and revenue
On Jul 16, 2026, DBVT reported earnings of -0.12 USD per share (EPS) for Q2 26, missing the estimate of -0.10 USD, resulting in a -18.81% surprise. Revenue reached 700.00 thousand, compared to an expected 1.40 million, with a -50.17% difference. The market reacted with a -1.08% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.09 USD, with revenue projected to reach 828.20 thousand USD, implying an decrease of -25.00% EPS, and increase of 18.31% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were DBV Technologies S.A. - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, DBV Technologies S.A. - ADR reported EPS of -$0.12, missing estimates by -18.81%, and revenue of $700.00K, -50.17% below expectations.
How did the market react to DBV Technologies S.A. - ADR's Q2 2026 earnings?
The stock price moved down -1.08%, changed from $14.86 before the earnings release to $14.70 the day after.
When is DBV Technologies S.A. - ADR expected to report next?
The next earning report is scheduled for Oct 28, 2026.
What are the forecasts for DBV Technologies S.A. - ADR's next earnings report?
Based on --
analysts, DBV Technologies S.A. - ADR is expected to report EPS of -$0.09 and revenue of $828.20K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.